TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9772585

Group type: EXPERIMENTAL
Intervention: Combination therapy of Western and traditional Chinese medicine (Astragalus membranaceus, taurine, coenzyme Q10, antiarrhythmics)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional therapy (glucose‐insulin‐potassium (GIK), coenzyme Q10, antiarrhythmics)
Number of subjects: 48
Study: 1305661

Group type: EXPERIMENTAL
Intervention: Nasal septal deformity screening
Number of subjects: 674

Group type: COMPARATOR
Intervention: Different types of delivery
Number of subjects: 674

Group type: COMPARATOR
Intervention: Degree of difficulty of delivery
Number of subjects: 674
Study: 4055045

Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 356

Group type: COMPARATOR
Intervention: Cefazolin
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Cefotaxime (sub-group with Staphylococcus aureus pneumonia)
Number of subjects: 356

Group type: COMPARATOR
Intervention: Cefazolin (sub-group with Staphylococcus aureus pneumonia)
Number of subjects: 356
Study: 30098230

Group type: EXPERIMENTAL
Intervention: Moderate Sedation (MS)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Deep Sedation (DS)
Number of subjects: 107
Study: 29116416

Group type: EXPERIMENTAL
Intervention: Psychosocial education intervention (Seeking Safety topics)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Usual prenatal care setting (Control)
Number of subjects: 149
Study: 24979303

Group type: EXPERIMENTAL
Intervention: SBP target <145-135 mmHg
Number of subjects: 7500

Group type: EXPERIMENTAL
Intervention: SBP target <135-125 mmHg
Number of subjects: 7500

Group type: EXPERIMENTAL
Intervention: SBP target <125 mmHg
Number of subjects: 7500

Group type: EXPERIMENTAL
Intervention: LDL-C target A (2.8-1.8 mmol/l)
Number of subjects: 7500

Group type: EXPERIMENTAL
Intervention: LDL-C target B (<1.8 mmol/l)
Number of subjects: 7500

Group type: EXPERIMENTAL
Intervention: SBP targets (all three)
Number of subjects: 7500
Study: 22248497

Group type: EXPERIMENTAL
Intervention: Galactose (GAL) supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glucose-maltodextrin (GLUC) supplementation
Number of subjects: 0
Study: 19675505

Group type: EXPERIMENTAL
Intervention: Tapering down of combined estrogen plus progestogen therapy (EPT)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Abrupt discontinuation of combined estrogen plus progestogen therapy (EPT)
Number of subjects: 81
Study: 17395393

Group type: EXPERIMENTAL
Intervention: CO2 inhalation test (exam group)
Number of subjects: 129

Group type: COMPARATOR
Intervention: CO2 inhalation test (non-exam group)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: CO2 inhalation test (both groups)
Number of subjects: 129
Study: 15760959

Group type: EXPERIMENTAL
Intervention: Hysteroscopic polypectomy
Number of subjects: 215

Group type: COMPARATOR
Intervention: Diagnostic hysteroscopy and polyp biopsy
Number of subjects: 215
Study: 14619265

Group type: EXPERIMENTAL
Intervention: Hospital at home services
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional hospital care
Number of subjects: 0
Study: 9891943

Group type: EXPERIMENTAL
Intervention: Intracoronary stenting (Palmaz‐Schatz) after PTCA
Number of subjects: 114

Group type: COMPARATOR
Intervention: PTCA alone (without stenting)
Number of subjects: 114
Study: 7973660

Group type: EXPERIMENTAL
Intervention: Cholinergic antagonist, tropicamide, placed in the eyes of patients with Alzheimer's disease
Number of subjects: 51

Group type: COMPARATOR
Intervention: Normal elderly controls
Number of subjects: 51
Study: 2637679

Group type: EXPERIMENTAL
Intervention: Morphine administered via buccal route (controlled release formulation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Morphine-3-glucuronide and morphine-6-glucuronide
Number of subjects: 0
Study: 29910016

Group type: EXPERIMENTAL
Intervention: In-session commitment statements (strength, frequency, and slope of strength) made in two therapy sessions
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: In-session commitment statements
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ecological momentary assessment (EMA) commitment to abstain
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Low pre-treatment commitment to abstain and increasing commitment strength across a session
Number of subjects: 48
Study: 29046197

Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 77
Study: 26046730

Group type: EXPERIMENTAL
Intervention: Intracoronary BMMC injection
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: G‐CSF mobilization (10 μg/kg/day subcutaneously for 5 days)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combination of BMMC injection plus G‐CSF
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional treatment (control group)
Number of subjects: 120
Study: 23239554

Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibitor treatment for 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 0
Study: 21987641

Group type: EXPERIMENTAL
Intervention: Crossed legs group
Number of subjects: 34
Study: 18450927

Group type: EXPERIMENTAL
Intervention: CBT4CBT (computer-based cognitive-behavioral therapy)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 77
Study: 16556794

Group type: EXPERIMENTAL
Intervention: Oral proton pump inhibitor (pantoprazole 20 mg)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 12967069

Group type: EXPERIMENTAL
Intervention: Topical anesthetic agent
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Pressure anesthesia with cotton tip applicator
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Combination of topical anesthetic and pressure anesthesia
Number of subjects: 15

Group type: COMPARATOR
Intervention: No site preparation (non-placebo control)
Number of subjects: 15
Study: 10741595

Group type: EXPERIMENTAL
Intervention: Rapid induction analgesia (RIA) conducted twice on 15 patients
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual dressing changes in 15 control patients
Number of subjects: 30
Study: 8723449

Group type: EXPERIMENTAL
Intervention: Meropenem monotherapy
Number of subjects: 958

Group type: COMPARATOR
Intervention: Ceftazidime plus amikacin combination therapy
Number of subjects: 958
Study: 8480868

Group type: EXPERIMENTAL
Intervention: Ivermectin at 20, 50, 100, and 200 micrograms/kg
Number of subjects: 40
Study: 3946501

Group type: EXPERIMENTAL
Intervention: Aluminum cannula
Number of subjects: 200

Group type: COMPARATOR
Intervention: Other cannulas
Number of subjects: 200
Study: 30251977

Group type: EXPERIMENTAL
Intervention: BCI-supported mental practice
Number of subjects: 55

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 55
Study: 26109251

Group type: EXPERIMENTAL
Intervention: Dabigatran (150 mg bid)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Phenprocoumon (INR 2-3)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 110

Group type: COMPARATOR
Intervention: Phenprocoumon
Number of subjects: 110
Study: 24477762

Group type: EXPERIMENTAL
Intervention: Grip force with eyes open
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Grip force with larger initial aperture
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Grip force after aperture changes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Grip force during aperture increase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Grip force during aperture contraction
Number of subjects: 0
Study: 23044498

Group type: EXPERIMENTAL
Intervention: 6% hydroxyl ethyl starch (HES) solution (Voluven)
Number of subjects: 92

Group type: COMPARATOR
Intervention: 4% gelatin
Number of subjects: 92

Group type: COMPARATOR
Intervention: Ringer's solution
Number of subjects: 92
Study: 20819983

Group type: EXPERIMENTAL
Intervention: Antipsychotic medication plus psychosocial intervention
Number of subjects: 1268

Group type: COMPARATOR
Intervention: Antipsychotic medication alone
Number of subjects: 1268
Study: 19033146

Group type: EXPERIMENTAL
Intervention: Tailored interactive sites
Number of subjects: 6451

Group type: COMPARATOR
Intervention: Less interactive ACS site
Number of subjects: 6451

Group type: EXPERIMENTAL
Intervention: Participants with depression
Number of subjects: 6451

Group type: EXPERIMENTAL
Intervention: Participants without depression
Number of subjects: 6451
Study: 15863204

Group type: EXPERIMENTAL
Intervention: IA plus IL‐11
Number of subjects: 100

Group type: COMPARATOR
Intervention: IA alone
Number of subjects: 100
Study: 12474761

Group type: EXPERIMENTAL
Intervention: Medications for osteoporosis treatment
Number of subjects: 0
Study: 10726111

Group type: EXPERIMENTAL
Intervention: High oleic acid (OA) diet (18.0 en%)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: High linoleic acid (LA) diet (11.5 en%)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (habitual diet)
Number of subjects: 38
Study: 8573640

Group type: EXPERIMENTAL
Intervention: Antipyrine estimation in saliva
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Saliva/plasma ACCl ratio
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Correlation between saliva and plasma APCl or APt1/2
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Slope of saliva/plasma APCl relationship
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Residual variance in regressions
Number of subjects: 116
Study: 1724102

Group type: EXPERIMENTAL
Intervention: Prostacyclin (PGI2) infusion of 10 or 20 ng/kg/min
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High-dose aprotinin substitution
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combination of prostacyclin and aprotinin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study: 6991541

Group type: EXPERIMENTAL
Intervention: Oral zomepirac 100 mg
Number of subjects: 159

Group type: COMPARATOR
Intervention: Intramuscular morphine 16 mg
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Oral zomepirac
Number of subjects: 159

Group type: COMPARATOR
Intervention: Intramuscular morphine
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 159
Study: 31687992

Group type: EXPERIMENTAL
Intervention: Excluding pelvic examination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Including pelvic examination
Number of subjects: 0
Study: 27548582

Group type: EXPERIMENTAL
Intervention: PLF (Posterolateral Fusion)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: TLIF (Transforaminal Lateral Interbody Fusion)
Number of subjects: 60

Group type: COMPARATOR
Intervention: PLF
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: TLIF
Number of subjects: 60
Study: 26132512

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) application (AIGaAs diode, 810 nm, 100 mW, 2J/cm(2), 15 seconds per point)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo group (simulated LLLT application)
Number of subjects: 30
Study: 24177006

Group type: EXPERIMENTAL
Intervention: Quality of life (QOL) assessment using stroke-specific QOL score, analyzed as a continuous variable (range 0-5)
Number of subjects: 2870

Group type: EXPERIMENTAL
Intervention: Factors associated with decline in QOL over time
Number of subjects: 2870
Study: 21289587

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) 15 mg/kg body weight intravenously before incision
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 40
Study: 19996037

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 240
Study: 18334772

Group type: EXPERIMENTAL
Intervention: Constraint Induced Movement Therapy (CIMT)
Number of subjects: 169
Study: 14733779

Group type: EXPERIMENTAL
Intervention: Chronic hepatitis C patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal controls (NC)
Number of subjects: 0
Study: 11282177

Group type: EXPERIMENTAL
Intervention: Aerosolized rhDNase (2.5 mg daily) for 3 months
Number of subjects: 21

Group type: COMPARATOR
Intervention: Aerosolized placebo for 3 months
Number of subjects: 21
Study: 9467148

Group type: EXPERIMENTAL
Intervention: Immediate diagnosis and treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cytological surveillance
Number of subjects: 0
Study: 7953261

Group type: EXPERIMENTAL
Intervention: Air insufflation
Number of subjects: 200

Group type: COMPARATOR
Intervention: Water irrigation
Number of subjects: 200
Study: 2885986

Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Number of subjects: 191

Group type: COMPARATOR
Intervention: Aurothioglucose
Number of subjects: 191
Study: 27526692

Group type: EXPERIMENTAL
Intervention: Multimedia educational tools (pamphlet and video)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pamphlet only
Number of subjects: 0
Study: 26832449

Group type: EXPERIMENTAL
Intervention: Photoselective vaporization of the prostate (PVP)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Plasmakinetic resection of prostate (PKRP)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: PVP
Number of subjects: 120

Group type: COMPARATOR
Intervention: PKRP
Number of subjects: 120
Study: 25119609

Group type: EXPERIMENTAL
Intervention: IIV3-HD (60 μg of hemagglutinin per strain)
Number of subjects: 31989

Group type: COMPARATOR
Intervention: IIV3-SD (15 μg of hemagglutinin per strain)
Number of subjects: 31989

Group type: EXPERIMENTAL
Intervention: IIV3-HD
Number of subjects: 31989

Group type: COMPARATOR
Intervention: IIV3-SD
Number of subjects: 31989
Study: 23181790

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 20736672

Group type: EXPERIMENTAL
Intervention: Perspective-taking instruction
Number of subjects: 608

Group type: COMPARATOR
Intervention: Neutral instruction
Number of subjects: 608
Study: 19032175

Group type: EXPERIMENTAL
Intervention: Clamping method with BrAC-guided adjustments to maintain stable BrAC levels of 0.6 g l(‐1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Two-step prekinetic procedure with a target BrAC of 0.65 g l(‐1)
Number of subjects: 0
Study: 15707951

Group type: COMPARATOR
Intervention: SNP rs348624
Number of subjects: 664

Group type: COMPARATOR
Intervention: Haplotypes constructed from three SNPs including rs348624
Number of subjects: 664
Study: 12765659

Group type: EXPERIMENTAL
Intervention: Homemade liquid supplement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard ward diet
Number of subjects: 0
Study: 10589806

Group type: EXPERIMENTAL
Intervention: SRP plus subgingival application of metronidazole 25% dental gel (Elyzol) 5x during 10 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 30
Study: 8611355

Group type: EXPERIMENTAL
Intervention: Children with chronic renal failure on a well‐balanced protein‐restricted diet
Number of subjects: 39

Group type: COMPARATOR
Intervention: Children with chronic renal failure with a normal protein intake
Number of subjects: 39

Group type: COMPARATOR
Intervention: Healthy children
Number of subjects: 39
Study: 1755555

Group type: EXPERIMENTAL
Intervention: Intranasal midazolam (IN) 0.15 mg.kg‐1
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Intramuscular midazolam (IM) 0.15 mg.kg‐1
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 29
Study: 6136794

Group type: EXPERIMENTAL
Intervention: Y-system (sodium hypochlorite)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard CAPD method
Number of subjects: 62
Study: 31818232

Group type: EXPERIMENTAL
Intervention: Curcumin (250 mg/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (250 mg/day)
Number of subjects: 50
Study: 31839626

Group type: EXPERIMENTAL
Intervention: Incremental sit-to-stand (ISTS) exercise
Number of subjects: 22
Study: 28560655

Group type: EXPERIMENTAL
Intervention: BioResponse DIM® (BR-DIM) at 150 mg twice daily
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 26956258

Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Time from symptom onset to reperfusion (OTR)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Time from onset to CT
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Time from CT to reperfusion
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: OTR time in ASPECTS<8 patients
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: OTR time in ASPECTS≥8 patients
Number of subjects: 103
Study: 24370467

Group type: EXPERIMENTAL
Intervention: PPPM
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: FPS‐R
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: PPPM and FPS‐R
Number of subjects: 174
Study: 22535515

Group type: EXPERIMENTAL
Intervention: Cooperative context
Number of subjects: 0

Group type: COMPARATOR
Intervention: Competitive context
Number of subjects: 0
Study: 19574776

Group type: EXPERIMENTAL
Intervention: Surgery plus vaginal irradiation (319 patients)
Number of subjects: 645

Group type: COMPARATOR
Intervention: Surgery alone (326 patients)
Number of subjects: 645
Study: 16858613

Group type: EXPERIMENTAL
Intervention: 12-month physical training programme (TRN)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (CTRL)
Number of subjects: 19
Study: 15316515

Group type: EXPERIMENTAL
Intervention: Environmental control measures attempted by parents (82% of parents attempted at least one measure)
Number of subjects: 896
Study: 11737019

Group type: EXPERIMENTAL
Intervention: Global motor rating scale measuring postural‐motor, locomotor (PML), and eye‐hand grip coordination (EHGC).
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Global motor rating scale.
Number of subjects: 123
Study: 9679572

Group type: EXPERIMENTAL
Intervention: D2 lymphadenectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: D4 lymphadenectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with oral fluorouracil
Number of subjects: 0
Study: 8023998

Group type: EXPERIMENTAL
Intervention: Arginine vasopressin (AVP) infusion (plasma AVP 16-20 pg/ml)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study: 2920304

Group type: COMPARATOR
Intervention: Propranolol 40 mg, three times daily
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Disopyramide 200 mg single dose, three days after propranolol discontinuation
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Combination of propranolol and disopyramide
Number of subjects: 15
Study: 1093108

Group type: EXPERIMENTAL
Intervention: Methylphenidate (dosage range: 0.2 to 1.9 mg/kg)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 28791521

Group type: EXPERIMENTAL
Intervention: Interactive computer (IC) module
Number of subjects: 54

Group type: COMPARATOR
Intervention: In-person genetic counseling (GC)
Number of subjects: 54
Study: 27092929

Group type: EXPERIMENTAL
Intervention: Clinic-based (CB) low vision rehabilitation services
Number of subjects: 55

Group type: COMPARATOR
Intervention: Home-based (HB) low vision rehabilitation services
Number of subjects: 55
Study: 24119989

Group type: EXPERIMENTAL
Intervention: High K meal (36 mmol potassium)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Low K meal (6 mmol potassium)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both meals
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: High K meal and Low K meal
Number of subjects: 32
Study: 21789646

Group type: EXPERIMENTAL
Intervention: Dor fundoplication
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Toupet fundoplication
Number of subjects: 60

Group type: COMPARATOR
Intervention: Both interventions (Dor and Toupet)
Number of subjects: 60
Study: 20555276

Group type: EXPERIMENTAL
Intervention: Rest interval of 60 seconds (P60)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Rest interval of 90 seconds (P90)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Rest interval of 120 seconds (P120)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: All protocols (P60, P90, P120)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: P90 and P120
Number of subjects: 10
Study: 18455169

Group type: EXPERIMENTAL
Intervention: IV semapimod
Number of subjects: 242

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study: 16339502

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE) (0.625 mg/d)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: CEE plus medroxyprogesterone acetate (MPA) (2.5 mg/d)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 12801217

Group type: EXPERIMENTAL
Intervention: Rackets with string tension differences of up to 98 N (10 kg)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Participants wearing earplugs during the test
Number of subjects: 41
Study: 11040726

Group type: EXPERIMENTAL
Intervention: Interactive multimedia computer game for asthma self-management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual-care comparison
Number of subjects: 0
Study: 8888298

Group type: EXPERIMENTAL
Intervention: Relative motion during adaptation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stationary surround contours in the nonadapting eye
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Presence of surround contours during adaptation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Presence or absence of surround contours during the test phase
Number of subjects: 0
Study: 2069490

Group type: EXPERIMENTAL
Intervention: CCK‐4 50 micrograms
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: CCK‐4 25 micrograms
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 27
Study: 6876944

Group type: EXPERIMENTAL
Intervention: Propranolol (20 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Propranolol (40 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nicergoline (30 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nicergoline (15 mg) and Propranolol (20 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30935515

Group type: EXPERIMENTAL
Intervention: 2000 mg/day dried ginger powder for 12 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo capsules for 12 weeks
Number of subjects: 46
Study: 29351783

Group type: EXPERIMENTAL
Intervention: Regional citrate anticoagulation (RCA)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Saline flushes
Number of subjects: 25